Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $4.84 in the prior trading day, Humacyte Inc (NASDAQ: HUMA) closed at $4.45, down -8.07%. In other words, the price has decreased by -$8.07 from its previous closing price. On the day, 5.9 million shares were traded. HUMA stock price reached its highest trading level at $4.84 during the session, while it also had its lowest trading level at $4.26.
Ratios:
Our goal is to gain a better understanding of HUMA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.10 and its Current Ratio is at 1.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 11, 2023, initiated with a Buy rating and assigned the stock a target price of $6.
On August 14, 2023, Piper Sandler Upgraded its rating to Neutral which previously was Underweight and also upped its target price recommendation from $2.75 to $3.50.
On June 22, 2023, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $6.Cantor Fitzgerald initiated its Overweight rating on June 22, 2023, with a $6 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 18 ’24 when AYABUDGE LLC bought 811,172 shares for $4.44 per share.
Sebelius Kathleen sold 5,182 shares of HUMA for $28,004 on Sep 10 ’24. The Director now owns 40,276 shares after completing the transaction at $5.40 per share. On Sep 10 ’24, another insider, Dougan Brady W, who serves as the Director of the company, sold 288,674 shares for $5.23 each. As a result, the insider received 1,509,765 and left with 3,230,884 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUMA now has a Market Capitalization of 559443264 and an Enterprise Value of 605477632.
Stock Price History:
Over the past 52 weeks, HUMA has reached a high of $9.97, while it has fallen to a 52-week low of $2.35. The 50-Day Moving Average of the stock is -17.70%, while the 200-Day Moving Average is calculated to be -17.46%.
Shares Statistics:
The stock has traded on average 2.91M shares per day over the past 3-months and 3585390 shares per day over the last 10 days, according to various share statistics. A total of 103.67M shares are outstanding, with a floating share count of 99.94M. Insiders hold about 20.60% of the company’s shares, while institutions hold 28.57% stake in the company. Shares short for HUMA as of 1730332800 were 17250350 with a Short Ratio of 5.92, compared to 1727654400 on 16028146. Therefore, it implies a Short% of Shares Outstanding of 17250350 and a Short% of Float of 17.870001.
